Dr. David Bartlett | Surgical Oncology | Best Researcher Award

Dr. David Bartlett | Allegheny Health Network | United States

Dr. David L. Bartlett is a distinguished surgical oncologist and cancer researcher specializing in innovative cancer treatments. 🎗️ He earned his M.D. from the University of Texas Medical School at Houston and completed his residency at the Hospital of the University of Pennsylvania. 🏥 He further honed his expertise through fellowships at Memorial Sloan Kettering Cancer Center. Dr. Bartlett has held prestigious leadership roles at the National Cancer Institute, University of Pittsburgh, and Allegheny Health Network, where he currently serves as System Chair of the AHN Cancer Institute. His contributions to surgical oncology and cancer research have shaped modern treatment approaches. 🔬

Professional Profile:

ORCID

Suitability for Best Researcher Award

Dr. David L. Bartlett is an exceptional candidate for the Best Researcher Award due to his groundbreaking contributions to surgical oncology and cancer research. His extensive experience in oncologic surgery, innovative treatment methods, and leadership in major cancer institutions sets him apart as a leading figure in the field. His work has significantly advanced cancer treatment strategies, improving patient outcomes and shaping the future of oncology.

Education & Experience 🎓📜

B.A. – Rice University, Houston, Texas (1983) 🎓
M.D. – University of Texas Medical School at Houston (1987) 🩺
Residency – Surgery, Hospital of the University of Pennsylvania (1987-1993) 🏥
Fellowship – Surgical Oncology, Memorial Sloan Kettering Cancer Center (1993-1995) 🔬
Special Expert – Surgery Branch, National Cancer Institute (1995-1996) 🧬
Senior Investigator – National Cancer Institute (1996-2001) 🏥
Associate Professor – University of Pittsburgh (2001-2005) 📚
Chief, Surgical Oncology – University of Pittsburgh (2001-2011) 🏥
Bernard Fisher Endowed Professor of Surgery – University of Pittsburgh (2006-2020) 🎖️
System Chair – AHN Cancer Institute (2020-present) 🌍

Professional Development & Leadership 🏆

Dr. Bartlett has significantly advanced surgical oncology through leadership roles and contributions to professional societies. 🎗️ He has been actively involved in the Society of Surgical Oncology (SSO), serving as Vice President, President-Elect, and President. 🎖️ His work includes chairing the UPMC Robotic Oversight Committee, leading the Regional Cancer Therapies Annual Meeting, and contributing to the FDA’s Cellular, Tissues, and Gene Therapies Advisory Committee. 🏥 As an editorial board member for journals like Cancer Gene Therapy and Clinical Colorectal Cancer, he has influenced research directions. Currently, as System Chair of the AHN Cancer Institute, he continues to pioneer cancer treatment advancements. 🔬

Research Focus 🔍

Dr. Bartlett specializes in cancer immunotherapy, regional cancer therapies, and surgical oncology. 🎗️ His research explores gene and cellular therapies, hyperthermic intraperitoneal chemotherapy (HIPEC), and regional perfusion techniques to enhance cancer treatment. 🔬 His NIH-funded studies have led to groundbreaking approaches in treating peritoneal and advanced-stage malignancies. 🧬 He has played a key role in integrating robotics and precision medicine into oncological surgery. 🤖 His focus on personalized cancer treatments continues to impact global oncology practices. 🌍 Through his work, he has significantly improved patient outcomes and contributed to the evolution of cancer surgery. 🏥

Awards & Honors 🏅

Bernard Fisher Endowed Professor of Surgery – University of Pittsburgh (2006-2020) 🎖️
President – Society of Surgical Oncology (2019-2020) 🏆
Vice President – Society of Surgical Oncology (2017-2018) 🎗️
Editorial Board Member – Cancer Gene Therapy, Annals of Surgical Oncology 📖
Chair – UPMC Robotic Oversight Committee (2010-2014) 🤖
Treasurer – Society of Surgical Oncology (2014-2017) 💰
Board of Directors – James Ewing Foundation (2011-2018) 🏥
FDA Advisory Committee Member – Cellular, Tissues, and Gene Therapies (2014-present) 🧬

Publication Top Notes:

🧫 Intra-Tumoral CD8+:CD3+ Lymphocyte Density Ratio in Appendix Cancer Is a Tumor Volume- and Grade-Independent Predictor of Survival (2025) – Cancers 🏥
👁️ Precision in Tear Fluid Biomarker Discovery: Quantitative Proteomic Profiling of Small-Volume, Individual Samples Using Capillary Tube Collection (2025) – Biomedicines 🧪
🦠 Fecal Microbiome Composition Correlates with Pathologic Complete Response in Patients with Operable Esophageal Cancer Treated with Combined Chemoradiotherapy and Immunotherapy (2024) – Cancers 💊
🏥 Assessing the Long-Term Priorities of Pancreaticoduodenectomy Survivors (2024) – HPB ❤️
🧬 Intratumoral Delivery of Interleukin 9 via Oncolytic Vaccinia Virus Elicits Potent Antitumor Effects in Tumor Models (2024) –Cancer🔬

Prof. Dr. Yanchuan Li | Nanjing Medical University | China

Dr. Yanchuan Li (李砚川), born in 1985 in Pingxiang, Jiangxi, is a distinguished cancer immunology researcher. He earned his Ph.D. in Biochemistry and Molecular Biology from Peking Union Medical College (Tsinghua University School of Medicine) in 2016 under the mentorship of Academician Linfang Wang and Prof. Shao-Cong Sun. Currently, he is a Professor and Ph.D. advisor at Nanjing Medical University, focusing on tumor and immune research. His expertise spans lymphocyte receptor signaling, CAR-NKT cell therapy, and molecular immunology. His groundbreaking research has been published in Cell Research, Blood, JEM, and Nature Communications. He also serves as a reviewer for top journals like Cellular & Molecular Immunology, Nucleic Acids Research, and Molecular Therapy. 🎓🔍

Suitability for Best Researcher Award

Dr. Yanchuan Li is a highly suitable candidate for a Best Researcher Award due to his exceptional contributions to cancer immunology and molecular immunology. Dr. Li’s expertise in lymphocyte receptor signaling, CAR-NKT cell therapy, and tumor immunology has significantly advanced the understanding of immune regulation in cancer. His research impacts both fundamental immunological mechanisms and translational applications, making him a distinguished figure in the field.

Education & Experience 📚👨‍🔬

2012-2016 🎓 Ph.D. in Biochemistry & Molecular Biology – Peking Union Medical College (Tsinghua University School of Medicine)

2014-2016 🌎 Visiting Ph.D. Scholar – MD Anderson Cancer Center, USA (CSC Scholarship)

2016-2021 🧪 Postdoctoral Research Fellow – MD Anderson Cancer Center, USA

2021-2022 🏥 Research Scientist – MD Anderson Cancer Center, USA

2022-2023 🔬 Research Associate – Baylor College of Medicine, USA

2023-Present 🎓 Professor & Ph.D. Supervisor – Nanjing Medical University

Professional Development 🔬📈

Dr. Li’s research bridges fundamental tumor immunology and translational medicine, employing cell culture, gene manipulation, proteomics, and multi-omics approaches. His work utilizes CRISPR/Cas9 screening, single-cell analysis, and knockout mouse models to uncover key immune signaling mechanisms. His significant contributions to B cell function, CAR-NKT therapy, and immune regulation in major diseases are paving the way for innovative cancer treatments. He has played a key role in developing CAR-NKT cell therapies, including a clinical trial for relapsed neuroblastoma. His dedication to scientific excellence and interdisciplinary collaboration is shaping the future of cancer immunotherapy. 🏥🧬💡

Research Focus 🔍🦠

Dr. Li’s research covers tumor immunology and translational medicine, with key interests in:
1️⃣ B Cell Function & Autoimmunity – Exploring B cell activation in diseases like SLE & B cell leukemia. 🔬🦠
2️⃣ CAR-NKT Cell Therapy – Engineering NKT cells for safer and more effective cancer immunotherapy. 🎯💉
3️⃣ Molecular Mechanisms of Major Diseases – Utilizing multi-omics & disease models to investigate cancer progression, autoimmune disorders, and drug response. 🧪📊
4️⃣ Advanced Immuno-Analytical Techniques – Developing single-cell spatial transcriptomics, CRISPR-based screens, and novel proteomics to revolutionize cancer research. 🔍🔬

Publication Top Notes:

📢 Proinflammatory TLR signalling is regulated by a TRAF2-dependent proteolysis mechanism in macrophages – Cited by 97 🔬
🧬Anti-GD2 CAR-NKT cells in relapsed or refractory neuroblastoma: updated phase 1 trial interim results – Cited by 87 🏥
🦠 TBKBP1 and TBK1 form a growth factor signalling axis mediating immunosuppression and tumourigenesis – Cited by 78 🧫
🛡Cell intrinsic role of NF-κB-inducing kinase in regulating T cell-mediated immune and autoimmune responses – Cited by 67 🏋️
🧩 Preventing abnormal NF-κB activation and autoimmunity by Otub1-mediated p100 stabilization – Cited by 44 🏗
🦠 NIK signaling axis regulates dendritic cell function in intestinal immunity and homeostasis – Cited by 44 🦠
🔥 Peli1 facilitates NLRP3 inflammasome activation by mediating ASC ubiquitination – Cited by 43 🚀
🧠 Microglia promote autoimmune inflammation via the noncanonical NF-κB pathway – Cited by 42 🧠
🌿 Protective effect of melatonin on cigarette smoke‐induced restenosis in rat carotid arteries after balloon injury – Cited by 40 🌙
🦠 Intestinal epithelial TBK1 prevents differentiation of T-helper 17 cells and tumorigenesis in mice – Cited by 30 🏥